Leading Pharmaceuticals Come Together To Develop Potential Vaccine For Covid-19
Britain based leading vaccine company GlaxoSmithKline (GSK) is planning on rolling out a billion of its potential Covid-19 vaccines.This vaccine is being made in collaboration with Sanofi, a French multinational pharmaceutical company, and will be made available only by the second half of 2021.
Developing a vaccine for Covid-19 within 15-18 months will be quite an achievement. This speed up on the vaccine development is all thanks to the previous research on SARS, MERS and the prior coronaviruses.
This vaccine production is being produced at nine sites globally, and the manufacturers aim to make it available at the earliest . It is very early to talk about the pricing of the vaccine, but they are committed at making it available at affordable prices.
#WeWontRest in the search for a #COVID19 vaccine. Our Chief Medical Officer, GSK Vaccines, Thomas Breuer and Su-Peng Ng, VP Global Medical Head @Sanofi discuss why two of the world's largest vaccines companies have joined forces to fight #COVID19. Watch it now. ???? https://t.co/PlIMxuX9fo— GSK (@GSK) June 9, 2020
Similarly Johnsons & Johnsons (J&J) as on June 10 sped up the first in-human clinical trial of SARS-CoV-2 vaccine to be able to produce it by July end. This was earlier scheduled for September.
#BIODigital: How do we get from point A to point B the fastest in pursuit of a #COVID19 vaccine?— Johnson & Johnson Innovation (@JNJInnovation) June 9, 2020
“We learn from each other. We can enhance each other's approaches through information sharing.” Paul Stoffels, #JNJ pic.twitter.com/6fCuma9th2
Also, J&J is expanding their global partnerships to speed up the vaccine's production technology and manufacturing capabilities.
This random vaccine evaluation will be done on 1,045 healthy adults aged 18 to 55, and also on people older than 65 years.